Apollon Formularies Plc - Intention to Withdraw from AQUIS
Apollon Formularies Plc("Apollon" or the "Company")
Intention to Withdraw from AQUIS
- Apollon Formularies PLC (AQSE: APOL), an innovator in medical cancer research, announces
The Company continues to progress the divestment of its intellectual property, proprietary formulations and other assets associated with its cancer research business to a Canadian company in the same field, as announced on . Further information will be available in the Company general meeting circular, referred to below. However, Apollon can no longer support the high cost of being a quoted company while this process is concluding.
The Company is preparing and will shortly post a general meeting circular to shareholders who will in due course be asked to vote on a withdrawal resolution from the Aquis Growth Market.
There will be no alternative exchange or platform to trade the Company's ordinary shares once withdrawal has taken place, however, the Company will explore potential mechanisms for the ongoing sale and purchase of its ordinary shares using platforms tailored to unlisted companies. It has not yet identified such a platform.
The directors of the Company accept responsibility for the contents of this announcement.
For additional information, please visit or contact:www.apollon.org.uk
Apollon Formularies
Tel: +44 771 198 0221Stene Jacobs
stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE